» Articles » PMID: 36601118

Radiomic Models Based on Magnetic Resonance Imaging Predict the Spatial Distribution of CD8 Tumor-infiltrating Lymphocytes in Breast Cancer

Overview
Journal Front Immunol
Date 2023 Jan 5
PMID 36601118
Authors
Affiliations
Soon will be listed here.
Abstract

Infiltration of CD8 T cells and their spatial contexture, represented by immunophenotype, predict the prognosis and therapeutic response in breast cancer. However, a non-surgical method using radiomics to evaluate breast cancer immunophenotype has not been explored. Here, we assessed the CD8 T cell-based immunophenotype in patients with breast cancer undergoing upfront surgery (n = 182). We extracted radiomic features from the four phases of dynamic contrast-enhanced magnetic resonance imaging, and randomly divided the patients into training (n = 137) and validation (n = 45) cohorts. For predicting the immunophenotypes, radiomic models (RMs) that combined the four phases demonstrated superior performance to those derived from a single phase. For discriminating the inflamed tumor from the non-inflamed tumor, the feature-based combination model from the whole tumor (RM-whole) showed high performance in both training (area under the receiver operating characteristic curve [AUC] = 0.973) and validation cohorts (AUC = 0.985). Similarly, the feature-based combination model from the peripheral tumor (RM-peri) discriminated between immune-desert and excluded tumors with high performance in both training (AUC = 0.993) and validation cohorts (AUC = 0.984). Both RM-whole and RM-peri demonstrated good to excellent performance for every molecular subtype. Furthermore, in patients who underwent neoadjuvant chemotherapy (n = 64), pre-treatment images showed that tumors exhibiting complete response to neoadjuvant chemotherapy had significantly higher scores from RM-whole and lower scores from RM-peri. Our RMs predicted the immunophenotype of breast cancer based on the spatial distribution of CD8 T cells with high accuracy. This approach can be used to stratify patients non-invasively based on the status of the tumor-immune microenvironment.

Citing Articles

Radiogenomics: bridging the gap between imaging and genomics for precision oncology.

He W, Huang W, Zhang L, Wu X, Zhang S, Zhang B MedComm (2020). 2024; 5(9):e722.

PMID: 39252824 PMC: 11381657. DOI: 10.1002/mco2.722.


Radiological Features for Predicting the Status of CD8-Positive Lymphocytes in HER2 Positive Breast Cancer.

Fan Y, Li X, Zhong P, Guo H, Han D, Tian W Balkan Med J. 2024; 41(3):213-221.

PMID: 38700366 PMC: 11077930. DOI: 10.4274/balkanmedj.galenos.2024.2024-2-64.


Radiomic Models Predict Tumor Microenvironment Using Artificial Intelligence-the Novel Biomarkers in Breast Cancer Immune Microenvironment.

Lin G, Wang X, Ye H, Cao W Technol Cancer Res Treat. 2023; 22:15330338231218227.

PMID: 38111330 PMC: 10734346. DOI: 10.1177/15330338231218227.

References
1.
Jeon S, Lim Y, Koh J, Chang W, Kim S, Kim K . A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8 cells in locally advanced rectal cancer. Radiother Oncol. 2021; 162:124-131. DOI: 10.1016/j.radonc.2021.07.004. View

2.
Emens L, Molinero L, Loi S, Rugo H, Schneeweiss A, Dieras V . Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021; 113(8):1005-1016. PMC: 8328980. DOI: 10.1093/jnci/djab004. View

3.
Savas P, Virassamy B, Ye C, Salim A, Mintoff C, Caramia F . Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018; 24(7):986-993. DOI: 10.1038/s41591-018-0078-7. View

4.
Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

5.
Hammerl D, Martens J, Timmermans M, Smid M, Trapman-Jansen A, Foekens R . Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021; 12(1):5668. PMC: 8476574. DOI: 10.1038/s41467-021-25962-0. View